ADVERTISEMENTs
.png)
BPGbio names Vijay Modur as chief medical officer
Dr Modur has previously worked with Zikani Therapeutics, Sanofi-Genzyme, HTG Molecular Diagnostics, Novartis Diagnostics, Novartis Oncology, and Merck & Co.
.jpg)
Dr Vijay Modur / (Image: LinkedIn profile)
Massachusetts-based artificial intelligence-powered (AI) biopharma, BPGbio has announced the appointment of Dr Vijay Modur as its chief medical officer (CMO), who will continue to advance the company's clinical trials.
Thrilled to join BPGbio, Dr Modur stated that artificial intelligence is revolutionizing traditional drug discovery and the company is at the forefront of using AI to harness the power of biology.
“I’m excited about the deep therapeutics and diagnostic pipeline BPGbio has, particularly those in late clinical stages, and I am looking forward to working with the BPGbio team to advance and commercialize our pipeline to help patient communities with unmet medical needs," he said.
Expressing honour and privilege to welcome Dr Modur to the company, its chief executive officer and president Niven R Narain stated that Dr Modur will bring his expertise in clinical development within the biotechnology and pharmaceutical industries, especially in the oncology and rare disease sectors. “BPGbio currently has five AI-guided and developed therapeutic assets in various stages of development, with potential considerations of an expanded Phase 3 asset. Adding him to our leadership team will help us accelerate the translational medicine focus necessary to advance clinical assets to fill the unmet needs of patients and families," Narain added.
Dr Modur's career has spanned multiple high-impact institutions and has orchestrated strategic initiatives that have elevated the development of therapies for rare and complex diseases.
Before joining BPGbio, he was Head of Research and Development at Eloxx Pharmaceuticals. He has held various leadership positions at Zikani Therapeutics, Sanofi-Genzyme, HTG Molecular Diagnostics, Novartis Diagnostics, Novartis Oncology, and Merck & Co. He earned his MBBS from Karnatak University, Dharwad, India and his PhD in experimental pathology from the University of Utah. He completed his residency training in the Department of Pathology and Laboratory Medicine at Washington University in St. Louis.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
E Paper
ADVERTISEMENT
.jpg)
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login